Clinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Gastric cancer is a common malignant tumour worldwide, and in China, the incidence and mortality rates of gastric cancer remain high. Standardised surgical treatment is effective, but the normal structure of the stomach undergoes irreversible changes, leading to a series of adverse reactions. At the same time, some early-stage gastric cancer patients cannot have the lesions completely removed endoscopically, and conventional surgery can affect postoperative normal life. Therefore, laparoscopic and endoscopic cooperative surgery has become a focus for precise stomach-preserving surgery. Participants meeting the surgical criteria are selected, and after discussing the treatment plan with their families and signing informed consent forms, relevant examinations are completed. During surgery, lesions are explored together using laparoscopy and endoscopy, then a fluorescent tracer is injected around the lesion and the lesion boundary is marked. Fifteen minutes after injecting the fluorescent tracer, the illuminated perigastric lymph nodes are the sentinel lymph node region (SLNB), and all fluorescent lymph nodes (sentinel lymph nodes) are removed and sent for intraoperative frozen pathology. If the SLNB is negative: a dual-endoscope combined local gastric resection (endoscope combined with laparoscopic local gastric resection or a modified procedure) is performed to completely remove the lesion, ensuring a negative margin. If the SLNB is positive: immediate conversion to laparoscopic-assisted radical gastrectomy (D2 lymph node dissection) is carried out. For SLNB-negative cases, the dual-endoscope combined local gastric resection specimen is placed in a retrieval bag for full removal and examination, with the stomach wall incision then closed by suturing or using a stapler. Postoperative follow-up includes monitoring tumour outcomes and quality of life.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony biopsją pojedynczy rak żołądka (adenocarcinoma)
- •Rak na wczesnym etapie (cT1N0M0) bez przerzutów potwierdzony badaniami obrazowymi
- •Zmiana nieprzydatna do endoskopowego leczenia ze względu na wielkość, umiejscowienie lub cechy morfologiczne
- •Zmiana o średnicy maksymalnie około 5 cm
- •Ogólny stan zdrowia pozwalający na znieczulenie i operację laparoskopową (ECOG 0-1)
- •Pełna świadomość benefitów i ryzyk procedury, podpisana zgoda
✗ Disqualifies
- •Rak zaawansowany (cT2 lub wyżej) lub przerzuty do węzłów chłonnych lub narządów
- •Ciąża lub karmienie piersią
- •Przebyta poważna operacja w górnej części brzucha mogąca utrudnić zabieg
- •Nawrotowy rak żołądka lub wcześniejsza chemioterapia/radioterapia
- •Alergja na fluorescencyjny barwnik używany w procedurze
- •Poprzednio udane endoskopowe usunięcie guza (eCura-)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- October 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Qingdao University Affiliated Hospital West Coast Campus
Qingdao, China
Gastrointestinal Surgery at Qingdao University Affiliated Hospital
Qingdao, China
Trial contact
dongsheng wang Dr wang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.